Skip to main content
. 2014 Apr 4;120(13):2006–2015. doi: 10.1002/cncr.28696

Figure 4.

Figure 4

Clinical and TumorGraft data are illustrated for patient POS-1207. (A) Histology of the TumorGraft confirms Ewing sarcoma. (B) TumorGraft sensitivity testing was performed to determine which drugs would be effective against the patient's tumor. A combination of docetaxel, gemcitabine, and bevacizumab proved effective using TumorGraft technology. Asterisks denote significance (a single asterisk indicates P ≤ .05; double asterisks, P ≤ .01; triple asterisks, P ≤ .001). (C) Radiology reports for patient POS-1119 demonstrate a partial response after treatment with ifosfamide.